DESTINY-Breast05: Additional Data From the Interim Analysis

In the interim analysis of DESTINY-Breast05, T-DXd demonstrated a significant and clinically meaningful improvement in invasive disease-free survival vs T-DM1 in patients with high-risk HER2+ primary breast cancer with residual invasive disease after neoadjuvant therapy. The safety profile remained manageable, with adjudicated drug-related ILD being mostly low grade and no difference in ILD incidence based on the timing of adjuvant radiation therapy. Rates of radiation pneumonitis were comparable between treatment arms. These findings support T-DXd as a new potential standard of care in this post-neoadjuvant setting.